RUXOLITINIB FOR MYELOFIBROSIS
Ruxolitinib for the treatment of myelofibrosis: an assessment based on the manufacturer’s submission to NICE
The aim of this NICE STA was to appraise the clinical and cost-effectiveness of ruxolitinib within its licensed indication for the treatment of myelofibrosis. CRD researchers comprise the Evidence Review Group for this STA. The work involved a detailed assessment of the manufacturer’s submission to NICE on the clinical and cost-effectiveness of ruxolitinib.
Myelofibrosis is a cancerous condition affecting the bone marrow, in which the marrow is replaced by scar (fibrous) tissue. Myelofibrosis may be primary, or secondary to a number of haematological, malignant, and non-malignant conditions.
Ruxolitinib (Jakavi, Novartis) is an orally administered protein kinase inhibitor, the antineoplastic activity of which is linked to the selective inhibition of the Janus-associated kinases (JAKs) involved in the signalling mediation of a number of cytokines and growth factors that are important for haematopoiesis and immune function.Conducted by: Dawn Craig1, Aileen Neilson1, Micah Rose1, Ros Wade1, Nerys Woolacott1
1. Centre for Reviews and Dissemination
Further detailsProject page on NIHR HTA Programme website
Related guidanceCommissioned to inform NICE Technology Appraisal Guidance: Ruxolitinib for the treatment of myelofibrosis. London: National Institute for Clinical Excellence; 2012
Commissioned by the NIHR HTA Programme in support of NICE's Single Technology Appraisal process.
NICE’s single technology appraisal (STA) process is specifically designed for the appraisal of a single product, device or other technology, with a single indication. The STA process normally covers new technologies and is designed to provide recommendations in the form of NICE guidance soon after the technology is introduced into the UK market. The principal evidence in the STA process is submitted by the manufacturer or sponsor of the technology.